These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37190093)

  • 1. Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer's Disease: Systematic Review and Meta-Analysis.
    Zabala-Findlay A; Penny LK; Lofthouse RA; Porter AJ; Palliyil S; Harrington CR; Wischik CM; Arastoo M
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis.
    Karikari TK; Emeršič A; Vrillon A; Lantero-Rodriguez J; Ashton NJ; Kramberger MG; Dumurgier J; Hourregue C; Čučnik S; Brinkmalm G; Rot U; Zetterberg H; Paquet C; Blennow K
    Alzheimers Dement; 2021 May; 17(5):755-767. PubMed ID: 33252199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Associations of Phosphorylated Tau 181 and Tau 231 Levels in Plasma and Cerebrospinal Fluid with Cognitive Function in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Li Z; Fan Z; Zhang Q
    J Alzheimers Dis; 2024; 98(1):13-32. PubMed ID: 38339929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios.
    Janelidze S; Barthélemy NR; He Y; Bateman RJ; Hansson O
    JAMA Neurol; 2023 May; 80(5):516-522. PubMed ID: 36987840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer's Disease and Mild Cognitive Impairment Patients.
    Shekhar S; Kumar R; Rai N; Kumar V; Singh K; Upadhyay AD; Tripathi M; Dwivedi S; Dey AB; Dey S
    PLoS One; 2016; 11(7):e0159099. PubMed ID: 27459603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrochemical impedance-based biosensor for label-free determination of plasma P-tau181 levels for clinically accurate diagnosis of mild cognitive impairment and Alzheimer's disease.
    Tieu MV; Choi SH; Le HTN; Cho S
    Anal Chim Acta; 2023 Sep; 1273():341535. PubMed ID: 37423666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients.
    Pichet Binette A; Palmqvist S; Bali D; Farrar G; Buckley CJ; Wolk DA; Zetterberg H; Blennow K; Janelidze S; Hansson O
    Alzheimers Res Ther; 2022 Mar; 14(1):46. PubMed ID: 35351181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylated tau in Alzheimer's disease.
    Telser J; Grossmann K; Wohlwend N; Risch L; Saely CH; Werner P
    Adv Clin Chem; 2023; 116():31-111. PubMed ID: 37852722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis.
    Chen L; Niu X; Wang Y; Lv S; Zhou X; Yang Z; Peng D
    Front Aging Neurosci; 2022; 14():942629. PubMed ID: 35959295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline.
    Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q;
    ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217.
    Groot C; Cicognola C; Bali D; Triana-Baltzer G; Dage JL; Pontecorvo MJ; Kolb HC; Ossenkoppele R; Janelidze S; Hansson O
    Alzheimers Res Ther; 2022 May; 14(1):67. PubMed ID: 35568889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential diagnosis of mild cognitive impairment of Alzheimer's disease by Simoa p-tau181 measurements with matching plasma and CSF.
    Wu L; Arvai S; Wang SJ; Liu AJ; Xu B
    Front Mol Neurosci; 2023; 16():1288930. PubMed ID: 38260807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
    Leuzy A; Janelidze S; Mattsson-Carlgren N; Palmqvist S; Jacobs D; Cicognola C; Stomrud E; Vanmechelen E; Dage JL; Hansson O
    Neurology; 2021 Oct; 97(17):e1681-e1694. PubMed ID: 34493616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
    JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease.
    Yang CC; Chiu MJ; Chen TF; Chang HL; Liu BH; Yang SY
    J Alzheimers Dis; 2018; 61(4):1323-1332. PubMed ID: 29376870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.
    Karikari TK; Benedet AL; Ashton NJ; Lantero Rodriguez J; Snellman A; Suárez-Calvet M; Saha-Chaudhuri P; Lussier F; Kvartsberg H; Rial AM; Pascoal TA; Andreasson U; Schöll M; Weiner MW; Rosa-Neto P; Trojanowski JQ; Shaw LM; Blennow K; Zetterberg H;
    Mol Psychiatry; 2021 Feb; 26(2):429-442. PubMed ID: 33106600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.